The Food and Drug Administration Friday approved a new dosage option for buprenorphine and naloxone sublingual film, applied under the tongue as a maintenance treatment for opioid dependence. The medication-assisted treatment was approved through an abbreviated pathway under the Federal Food, Drug, and Cosmetic Act, which may rely on the FDA’s finding that a previously approved drug is safe and effective. “There’s an urgent need to ensure access to, and wider use and understanding of, medication-assisted treatment for opioid use disorder,” said FDA Commissioner Scott Gottlieb, M.D. “The introduction of new treatment options has the potential to broaden access for patients.”
 

Related News Articles

Headline
The National Institutes of Health today selected several universities to partner with communities in Kentucky, Massachusetts, New York and Ohio to study the…
Headline
The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels.
Headline
The Agency for Healthcare Research and Quality is accepting comments through April 25 on a draft report on treatment for acute pain.
Headline
The Department of Health and Human Services this week awarded $487 million in fiscal year 2019 grants to help states and territories increase access to…
Headline
The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone —…
Headline
In a study of Blue Cross and Blue Shield enrollees reported last week in the New England Journal of Medicine, initial opioid prescriptions declined 54 percent…